




GSK at a glance

Ahead Together



Who we are

We are a focused biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

We aim to positively impact the health of more than 2.5 billion individuals by the end of the decade with ambitious plans for growth and continuing to make GSK a company where everyone can thrive.

What we do

We prevent and treat disease with specialty medicines, vaccines and general medicines.

We focus on the science of the immune system and advanced technologies, investing in 4 core therapeutic areas (respiratory, immunology and inflammation; oncology; HIV; and infectious diseases) to impact health at scale.

In 2024:

£31.4bn
medicines and vaccine sales

71 medicines and vaccines in development

£6.4bn
R&D investment

13 positive phase III readouts

We operate responsibly for all our stakeholders by prioritising Innovation, Performance and Trust.

Our portfolio:

Specialty Medicines



Our specialty medicines prevent and treat diseases, from HIV, cancer and asthma to immune-inflammation diseases like lupus.

Vaccines

Our broad vaccines portfolio targets infectious diseases at every stage of life.

General Medicines

From antibiotics to inhaled medicines for asthma and COPD, we have a broad portfolio of general medicine products, many of them leaders in their class, making life better for millions of people worldwide.



Our priorities

Innovation

We develop and launch new medicines and vaccines where they are needed, with better, faster and smarter R&D.

In 2024:

19

pipeline assets in phase III/ registration

12

new collaborations and acquisitions

Performance

Driven by our innovation, we have delivered consistent sales and profit growth and improved our long-term outlooks.

£31.4bn

medicines and vaccine sales

2.1bn

packs of medicines and vaccine doses delivered

Trust

We focus on issues that matter most to our business, our stakeholders, and society, and where we can have the greatest impact.

2nd

in the Access to Medicine Index

91%

of our Responsible Business Performance Rating metrics 'met' or 'exceeded'

Our culture

We have almost 70,000 people in 75 countries worldwide and culture at GSK is something we all own.

We are ambitious for patients

to deliver what matters better and faster.

We are accountable for impact

with clear ownership and support to succeed.

We do the right thing with integrity and care because people count on us.

This powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive.

These are the foundations for how, together, we'll deliver more for our patients, shareholders and GSK people.

Why we do it

We aim to get ahead of disease together – to positively impact the health of 2.5 billion people by the end of the decade.

